Q-omics provides the consensus-scored LRRC37A4P profile across patient tissues and cancer cell-line models. LRRC37A4P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRRC37A4P is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LRRC37A4P RNA expression shows 18,617 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where LRRC37A4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A4P survival associations across molecular data types. LRRC37A4P RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A4P RNA expression–survival associations across cancer types. High LRRC37A4P expression shows unfavorable associations in UVM, MESO and ESCA, but favorable associations in SKCM, HNSC and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRRC37A4P RNA expression.
This table summarizes LRRC37A4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A4P shows lower tumor expression in KIRC, BRCA, HNSC and KICH and higher tumor expression in COAD and UCEC. The KIRC box plot shows higher LRRC37A4P RNA expression in normal versus tumor tissue (log2 FC = −0.703, t-test p < 0.001).
This table shows molecular features associated with LRRC37A4P in patient tissues and cancer cell lines. In patient samples, LRRC37A4P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
